Q4 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$263M+103.1% YoY

Gross Profit

$167M63.5% margin

Operating Income

-$172M-65.2% margin

Net Income

-$119M-45.3% margin

EPS (Diluted)

$-1.74

QoQ Revenue Growth

+10.0%

Cash Flow

Operating Cash Flow

$105M

Free Cash Flow

$101M

Stock-Based Comp.

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$874M

Stockholders' Equity

$447M

Cash & Equivalents

$416M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$263M	$130M	+103.1%
Gross Profit	$167M	$58M	+188.7%
Operating Income	-$172M	-$35M	-385.8%
Net Income	-$119M	-$40M	-196.4%

Revenue Segments

Radiopharmaceutical Oncology

$162M31%

PYLARIFY

$161M31%

Total Precision Diagnostics

$94M18%

DEFINITY

$64M12%

Techne Lite

$25M5%

License and Royalty Revenues

$7M1%

Strategic Partnerships And Other

$7M1%

Other Precision Diagnostics

$6M1%

Other Radiopharmaceutical Oncology

$919,0000%